Cargando…

Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer

OBJECTIVE: Intraoperative radiotherapy (IORT) in early-stage breast cancer has been studied over the years. However, it has not been demonstrated whether IORT is more suitable as a therapeutic option for early-stage breast cancer than whole breast radiotherapy (WBRT). Therefore, we performed a meta-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Linwei, Sun, Min, Yang, Shuailong, Chen, Yuanyuan, Li, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716392/
https://www.ncbi.nlm.nih.gov/pubmed/34976796
http://dx.doi.org/10.3389/fonc.2021.737982
_version_ 1784624314704723968
author Wang, Linwei
Sun, Min
Yang, Shuailong
Chen, Yuanyuan
Li, Tian
author_facet Wang, Linwei
Sun, Min
Yang, Shuailong
Chen, Yuanyuan
Li, Tian
author_sort Wang, Linwei
collection PubMed
description OBJECTIVE: Intraoperative radiotherapy (IORT) in early-stage breast cancer has been studied over the years. However, it has not been demonstrated whether IORT is more suitable as a therapeutic option for early-stage breast cancer than whole breast radiotherapy (WBRT). Therefore, we performed a meta-analysis to compare the efficacy and safety of IORT to those of WBRT as therapeutic options for early-stage breast cancer patients receiving breast-conserving surgery (INPLASY2020120008). METHODS: PubMed, Embase, and Cochrane Library databases were searched from inception to October 2021. Computerized and manual searches were adopted to identify eligible randomized control trials from online databases. Risk ratio (RR) and 95% confidence intervals (CI) were calculated by random-effect models to assess the relative risk. Potential publication bias was quantified by Begg’s and Egger’s tests. RESULTS: Based on our inclusion criteria, 10 randomized control trials involving 5,698 patients were included in this meta-analysis. This meta-analysis showed that the IORT group was associated with a higher local recurrence risk (RR = 2.111, 95% CI, 1.130–3.943, p = 0.0191), especially in the long-term follow-up subgroup or published after 2020 subgroup or Caucasian subgroup (RR = 2.404, 95% CI, 1.183–4.885, p = 0.0154). Subgroup analysis showed that the IORT group had a higher recurrence risk than the WBRT group in the polycentric randomized controlled trial subgroup (RR = 1.213, 95% CI, 1.030–1.428, p = 0.0204). Pooled analysis showed that there was no statistically significant difference in overall survival, recurrence-free survival, distant metastasis-free survival, and cancer-specific survival between IORT and WBRT groups. Additionally, the risk of skin toxicity was reduced, but the incidences of fat toxicity, edema, and scar calcification were significantly increased in the patients who underwent IORT in comparison to those who underwent WBRT. CONCLUSION: This meta-analysis revealed that IORT was not a better alternative to WBRT. More large-scale and well-designed clinical trials with longer follow-up periods are encouraged to further investigate the value of IORT. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2020-12-0008/.
format Online
Article
Text
id pubmed-8716392
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87163922021-12-31 Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer Wang, Linwei Sun, Min Yang, Shuailong Chen, Yuanyuan Li, Tian Front Oncol Oncology OBJECTIVE: Intraoperative radiotherapy (IORT) in early-stage breast cancer has been studied over the years. However, it has not been demonstrated whether IORT is more suitable as a therapeutic option for early-stage breast cancer than whole breast radiotherapy (WBRT). Therefore, we performed a meta-analysis to compare the efficacy and safety of IORT to those of WBRT as therapeutic options for early-stage breast cancer patients receiving breast-conserving surgery (INPLASY2020120008). METHODS: PubMed, Embase, and Cochrane Library databases were searched from inception to October 2021. Computerized and manual searches were adopted to identify eligible randomized control trials from online databases. Risk ratio (RR) and 95% confidence intervals (CI) were calculated by random-effect models to assess the relative risk. Potential publication bias was quantified by Begg’s and Egger’s tests. RESULTS: Based on our inclusion criteria, 10 randomized control trials involving 5,698 patients were included in this meta-analysis. This meta-analysis showed that the IORT group was associated with a higher local recurrence risk (RR = 2.111, 95% CI, 1.130–3.943, p = 0.0191), especially in the long-term follow-up subgroup or published after 2020 subgroup or Caucasian subgroup (RR = 2.404, 95% CI, 1.183–4.885, p = 0.0154). Subgroup analysis showed that the IORT group had a higher recurrence risk than the WBRT group in the polycentric randomized controlled trial subgroup (RR = 1.213, 95% CI, 1.030–1.428, p = 0.0204). Pooled analysis showed that there was no statistically significant difference in overall survival, recurrence-free survival, distant metastasis-free survival, and cancer-specific survival between IORT and WBRT groups. Additionally, the risk of skin toxicity was reduced, but the incidences of fat toxicity, edema, and scar calcification were significantly increased in the patients who underwent IORT in comparison to those who underwent WBRT. CONCLUSION: This meta-analysis revealed that IORT was not a better alternative to WBRT. More large-scale and well-designed clinical trials with longer follow-up periods are encouraged to further investigate the value of IORT. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2020-12-0008/. Frontiers Media S.A. 2021-12-16 /pmc/articles/PMC8716392/ /pubmed/34976796 http://dx.doi.org/10.3389/fonc.2021.737982 Text en Copyright © 2021 Wang, Sun, Yang, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Linwei
Sun, Min
Yang, Shuailong
Chen, Yuanyuan
Li, Tian
Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer
title Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer
title_full Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer
title_fullStr Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer
title_full_unstemmed Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer
title_short Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer
title_sort intraoperative radiotherapy is not a better alternative to whole breast radiotherapy as a therapeutic option for early-stage breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716392/
https://www.ncbi.nlm.nih.gov/pubmed/34976796
http://dx.doi.org/10.3389/fonc.2021.737982
work_keys_str_mv AT wanglinwei intraoperativeradiotherapyisnotabetteralternativetowholebreastradiotherapyasatherapeuticoptionforearlystagebreastcancer
AT sunmin intraoperativeradiotherapyisnotabetteralternativetowholebreastradiotherapyasatherapeuticoptionforearlystagebreastcancer
AT yangshuailong intraoperativeradiotherapyisnotabetteralternativetowholebreastradiotherapyasatherapeuticoptionforearlystagebreastcancer
AT chenyuanyuan intraoperativeradiotherapyisnotabetteralternativetowholebreastradiotherapyasatherapeuticoptionforearlystagebreastcancer
AT litian intraoperativeradiotherapyisnotabetteralternativetowholebreastradiotherapyasatherapeuticoptionforearlystagebreastcancer